Entia Biosciences, Inc. Stock

Equities

ERGO

US29384E1047

Biotechnology & Medical Research

Market Closed - OTC Markets 11:08:19 2024-03-25 am EDT 5-day change 1st Jan Change
0.0001 USD -.--% Intraday chart for Entia Biosciences, Inc. -.--% -.--%
Sales 2015 347K Sales 2016 265K Capitalization 1.58M
Net income 2015 -2M Net income 2016 -1M EV / Sales 2015 8.29 x
Net Debt 2015 255K Net Debt 2016 970K EV / Sales 2016 9.59 x
P/E ratio 2015
-0.97 x
P/E ratio 2016
-1.13 x
Employees 7
Yield 2015 *
-
Yield 2016
-
Free-Float 99.44%
More Fundamentals * Assessed data
Dynamic Chart
Current year
0.00
Extreme 0.0001
0.00
1 year
0.00
Extreme 0.0001
0.00
3 years
0.00
Extreme 0.0001
0.39
5 years
0.00
Extreme 0.0001
0.39
10 years
0.00
Extreme 0.0001
0.73
More quotes
Managers TitleAgeSince
Chief Executive Officer 67 15-09-30
More insiders
Entia Biosciences, Inc. develops pharmaceutical-grade organic compounds, including a foundational compound called ErgoD2. The Company also develops and markets health-related nutraceuticals and cosmeceuticals. ErgoD2 is a pharmaceutical-grade organic compound created from whole foods that contain the micro-nutrients L-ergothioneine, an amino acid that has a transporter (SLC22A4) in every human being, and vitamin D2. ErgoD2 improves iron homeostasis and mitigates iron-related disorders presenting in anemia, chronic kidney disease and select neurodegenerative diseases. The Company's ErgoD2 formulations utilize organically cultivated specialty mushrooms available from various domestic and international suppliers. These mushroom-based products are generally regarded as safe (GRAS). The Company's market and scientific research has identified mushroom species and suppliers to provide the nutritional profiles for its ErgoD2 formulations.
More about the company